Hadas Reuveni
Hoofd Techniek/Wetenschap/O&O bij PURPLE BIOTECH LTD
Profiel
Hadas Reuveni was the founder of AngioB Ltd.
where she held the title of Chief Scientific Officer from 2006 to 2010.
Dr. Reuveni is also the founder of Tyrnovo Ltd.
She is currently the Vice President-Research & Development at Purple Biotech Ltd.
since 2017.
Dr. Reuveni's former positions include Chief Executive Officer at NovoTyr Therapeutics Ltd.
from 2005 to 2012 and Director-Research & Development at Keryx Biopharmaceuticals, Inc. from 2001 to 2004.
Dr. Reuveni received her undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Actieve functies van Hadas Reuveni
| Bedrijven | Functie | Begin |
|---|---|---|
| PURPLE BIOTECH LTD | Hoofd Techniek/Wetenschap/O&O | 01-01-2017 |
Tyrnovo Ltd.
 Tyrnovo Ltd. Drugstore ChainsRetail Trade Tyrnovo Ltd. operates as a pharmaceutical company. It develops drugs that eliminates a key protein in cancer, resulting in improved cancer therapy, prevention of drug resistance, and increased life expectancy. The company was founded by Hadas Reuveni and is headquartered in Herzliya, Israel. | Algemeen Directeur | - |
Eerdere bekende functies van Hadas Reuveni
| Bedrijven | Functie | Einde |
|---|---|---|
NovoTyr Therapeutics Ltd.
 NovoTyr Therapeutics Ltd. Medical SpecialtiesHealth Technology NovoTyr Therapeutics Ltd. develops insulin-like growth factor receptor inhibitors. It provides services in the biotechnology, drug development, cancer and other proliferative disease sectors. The company was founded by Alexander Levitzki in 2005 and is headquartered in Kiryat Shmona, Israel | Algemeen Directeur | 01-01-2012 |
| KERYX BIOPHARMACEUTICALS | Hoofd Techniek/Wetenschap/O&O | 01-01-2004 |
AngioB Ltd.
 AngioB Ltd. Medical SpecialtiesHealth Technology AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel | Oprichter | - |
Opleiding van Hadas Reuveni
| The Hebrew University of Jerusalem | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PURPLE BIOTECH LTD | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
AngioB Ltd.
AngioB Ltd. Medical SpecialtiesHealth Technology AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel | Health Technology |
NovoTyr Therapeutics Ltd.
NovoTyr Therapeutics Ltd. Medical SpecialtiesHealth Technology NovoTyr Therapeutics Ltd. develops insulin-like growth factor receptor inhibitors. It provides services in the biotechnology, drug development, cancer and other proliferative disease sectors. The company was founded by Alexander Levitzki in 2005 and is headquartered in Kiryat Shmona, Israel | Health Technology |
Tyrnovo Ltd.
Tyrnovo Ltd. Drugstore ChainsRetail Trade Tyrnovo Ltd. operates as a pharmaceutical company. It develops drugs that eliminates a key protein in cancer, resulting in improved cancer therapy, prevention of drug resistance, and increased life expectancy. The company was founded by Hadas Reuveni and is headquartered in Herzliya, Israel. | Retail Trade |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
